MIST today
$0.66+$0.00 (+0.00%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bullish
15 minStrong Bearish
5 minSymmetric Triangle
Daily trend turns up above $0.81
Key levels
Resistance$0.80
Resistance$0.72
Support$0.63
Latest news & SEC filings
NewsMilestone Pharmaceuticals wins 2026 BioTech Breakthrough Award
NewsMilestone Pharmaceuticals Discloses New Stock Awards
ProductMilestone Pharmaceuticals says CARDAMYST helped PSVT patients after ablation
All MIST news →About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company that develops and sells cardiovascular medicines. Its lead commercial offering is a self-administered nasal spray containing etripamil, a prescription therapy for adults who experience sudden episodes of a rapid heart rhythm disorder known as PSVT, and it is sold in the United States. The company is also studying etripamil for an irregular, fast heartbeat condition affecting the upper chambers of the heart, and it has licensed rights for several Asian markets to Corxel Pharmaceuticals. Its customers include cardiologists, heart rhythm specialists, and patients with cardiac arrhythmias.
Based on the company's 10-K filed Mar 20, 2026.
Nasdaq · Healthcare
Milestone Pharmaceuticals Inc. (MIST)
What Is the Price Target for MIST?
SEPT Low Target
$3.00
SEPT Mid Target
$5.00
SEPT High Target
$7.00
Analyst Consensus
$5.00
Is MIST a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MIST.
Start Free Trial →Is MIST Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$5.00
2
Moat Score
NONE
2/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with MIST?
Insider Signal
SELLING
0 buys / 13 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MIST Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-11.94%
FCF Growth YoY
-70.8%
Revenue Trend
UNKNOWN
Dark Pool Trades for MIST
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MIST, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:59:15 | $0.67 | 5,000 | $$3K | MIDPOINT |
| 20:55:59 | $0.68 | 1,100 | $$753 | SELL |
| 20:55:57 | $0.69 | 1,178 | $$809 | SELL |
| 20:55:52 | $0.69 | 1,053 | $$721 | MIDPOINT |
| 20:39:26 | $0.67 | 2,900 | $$2K | SELL |
5 dark pool trades shown · $$8K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Milestone Pharmaceuticals Inc. (MIST) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MIST — frequently asked questions
What is MIST stock price today?
Milestone Pharmaceuticals Inc. (MIST) is at $0.66, up 0.00% (+$0.00) at the Nov 11, 2026 close.
Why is MIST stock moving today?
Latest MIST news — Nov 6, 2026: Milestone Pharmaceuticals wins 2026 BioTech Breakthrough Award · Nov 4, 2026: Milestone Pharmaceuticals Discloses New Stock Awards
What is the MIST price target?
The average analyst price target for MIST is $5.00, ranging from $3 to $7, based on 2 analysts. Latest: Cantor Fitzgerald initiates on Aug 20, 2026.
What do analysts rate MIST?
Analyst ratings for MIST: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did MIST beat earnings?
MIST last reported on Aug 12, 2026: EPS -$0.21 vs -$0.20 expected — a miss of 7.7%.
Does MIST pay a dividend?
MIST does not currently pay a dividend.
How much debt does MIST have?
Milestone Pharmaceuticals Inc. reported $59M of debt and $170M of cash (Jun 30, 2026).
What are MIST support and resistance levels?
Support: $0.63. Resistance: $0.72, $0.80, $0.90.
What are insiders doing with MIST?
Insider activity: SELLING, 0 buys and 13 sells in the last 90 days.
What is the latest news on MIST?
Nov 6, 2026: Milestone Pharmaceuticals wins 2026 BioTech Breakthrough Award · Nov 4, 2026: Milestone Pharmaceuticals Discloses New Stock Awards · Nov 3, 2026: Milestone Pharmaceuticals says CARDAMYST helped PSVT patients after ablation